Depression

What The Study Did: Questionnaire responses were compared to examine whether transgender children and teens experience significantly higher levels of anxiety and depression than their cisgender peers. Authors: Dominic J. Gibson, Ph.D., of the University of Washington in Seattle, is the corresponding author. To access the embargoed study: Visit our For The Media website at […]

Key Prominent Players Covered in the Depression Treatment Therapy Market Research Report Are includes Pfizer Inc., Teva Pharmaceuticals, Merck & Co. Inc., Johnson & Johnson, Eli Lilly and Company, Novartis International AG, Sanofi S.A., AstraZeneca PLC, and others. Pune, India, April 07, 2021 (GLOBE NEWSWIRE) — The global ”depression treatment therapy market” size is expected

While anxiety and depression are extremely common and comorbid for adolescents, they often can go untreated. However, 1 option to improve this treatment gap is pediatric transdiagnostic interventions. A team, led by Frances L. Lynch, PhD, MSPH, Center for Health Research, Kaiser Permanente Northwest, evaluated the cost-effectiveness for pediatric transdiagnostic brief behavioral therapy (BBT) programs

Haiyan Jiao,1 Hongjun Yang,1 Zhiyi Yan,1 Jianbei Chen,1 Mengbai Xu,1 Youming Jiang,1 Yueyun Liu,1 Zhe Xue,1 Qingyu Ma,2 Xiaojuan Li,2 Jiaxu Chen1,2 1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China; 2Formula-Pattern Research center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, 510632, Guangdong, People’s Republic of China

As of 2019, over 50 million American adults live with a mental illness, and over 20 percent of American adults experience chronic pain. Cymbalta (duloxetine) is a drug commonly prescribed for these conditions, which include depression, anxiety, and certain chronic pain issues. As with all similar drugs, stopping Cymbalta can cause withdrawal side effects, some

Cuihua Zou,1,2,* Xiaohua Huang,1,2,* Xuequn Lan,1 Xiaorui Huang,1 Yun Feng,1 Jianmin Huang,1 Lanqing Meng,1 Chongdong Jian,1 Donghua Zou,3 Jie Wang,4 Xuebin Li1,2 1Department of Neurology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, 533000, People’s Republic of China; 2Department of Neurology, Youjiang Medical University for Nationalities, Baise, Guangxi, 533000, People’s Republic of

Sleep, body clocks and depression We know that only a fraction of people with mood disorders get access to treatment and fewer still get access to the right kind of treatment for their specific problems. To reduce this treatment gap, we are interested in zoning in on specific underlying mechanisms that are causing someone’s mood

Prof Dame Til Wykes, at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, said: “The study confirms our suspicions that a Covid-19 diagnosis is not just related to respiratory symptoms, it is also related to psychiatric and neurological problems.

Prof Dame Til Wykes, at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, said: “The study confirms our suspicions that a Covid-19 diagnosis is not just related to respiratory symptoms, it is also related to psychiatric and neurological problems.

SAINT-CLOUD, France, April 6, 2021 /PRNewswire/ — Ethypharm announces today that it has acquired exclusive rights for two CE-marked digital therapies, deprexis® and vorvida®, developed by GAIA AG (GAIA),  a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area